Evidence map›Paper›PMID 37466710›Full record

ArticleEuropean radiology2023

Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablation.

Raphaël Lehrer, Francois Cornelis, Jean-Christophe Bernhard, Pierre Bigot, Cécile Champy, Franck Bruyère, Morgan Rouprêt, Nicolas Doumerc, Charles-Karim Bensalah, Jonathan Olivier and 11 more

Open access · hybridAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 4 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 2 countries.

Raphaël LehrerDepartment of Radiology, Sorbonne Université, AP-HP, Hôpital Tenon, Paris, France.
Francois CornelisRadiology Department, Memorial Sloan Kettering Cancer Center, New York, USA.
Jean-Christophe BernhardFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Pierre BigotFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Cécile ChampyDepartment of Urology, University Hospital Henri Mondor, AP-HP, Créteil, France.
Franck BruyèreFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Morgan RouprêtFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Nicolas DoumercFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Charles-Karim BensalahFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Jonathan OlivierDepartment of Urology, Lille University Hospital, Lille, France.
François AudenetFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Thibault TricardDepartment of Urology, Nouvel Hôpital Civil, Strasbourg, France.
Bastien ParierDepartment of Urology, Bicêtre University Hospital, AP-HP, Le Kremlin-Bicêtre, France.
Xavier DurandDepartment of Urology, Paris Saint-Joseph Hospital, Paris, France.
Matthieu DurandDepartment of Urology, Hôpital Pasteur 2, Nice, France.
Thomas CharlesFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Nicolas BrangerDepartment of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.
Louis SurlemontDepartment of Urology, Rouen University Hospital, Rouen, France.
Evanguelos XylinasFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Jean-Baptiste BeauvalFrench Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Matthias BarralDepartment of Radiology, Sorbonne Université, AP-HP, Hôpital Tenon, Paris, France. matthias.barral@aphp.fr.
French Clinical Research Infrastructure Network · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Rennes · FRHôpital Bichat-Claude-Bernard · FRHôpital Civil, Strasbourg · FRHôpital Européen · FRHôpital Paris Saint-Joseph · FRHôpital Pasteur · FRHôpital Pellegrin · FRInserm · FRInstitut Paoli-Calmettes · FRMemorial Sloan Kettering Cancer Center · USSorbonne Université · FRUniversité de Rouen Normandie · FRUniversité de Tours · FR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
6 · The paper itself

Abstract

purposeTo compare the oncological and perioperative outcomes of robot-assisted partial nephrectomy (RPN) and percutaneous thermal ablation (PTA) for treatment of T1 renal cell cancer (RCC) in patients older than 75 years. MATERIALS AND

methodsRetrospective national multicenter study included all patients older than 75 years treated for a T1 RCC by RPN or PTA between January 2010 and January 2021. Patients' characteristics, tumor data, and perioperative and oncological outcomes were compared.

resultsA total of 205 patients for 209 procedures (143 RPN and 66 PTA) were included. In the PTA group, patients were older (80.4 ± 3.7 vs. 79 ± 3.7 years (p = 0.01)); frailer (ASA score (2.43 ± 0.6 vs. 2.17 ± 0.6 (p < 0.01)); and more frequently had a history of kidney surgery (16.7% [11/66] vs. 5.6% [8/143] (p = 0.01)) than in the RPN group. Tumors were larger in the RPN group (2.7 ± 0.7 vs. 3.2 ± 0.9 cm (p < 0.01)). Operation time, length of hospital stay, and increase of creatinine serum level were higher in RPN (respectively 92.1 ± 42.7 vs. 150.7 ± 61.3 min (p < 0.01); 1.7 ± 1.4 vs. 4.2 ± 3.4 days (p < 0.01); 1.9 ± 19.3% vs. 10.1 ± 23.7 (p = 0.03)). Disease-free survival and time to progression were similar (respectively, HR 2.2; 95% CI 0.88-5.5; p = 0.09; HR 2.1; 95% CI 0.86-5.2; p = 0.1). Overall survival was shorter for PTA that disappeared after Cox adjusting model (HR 3.3; 95% CI 0.87-12.72; p = 0.08).

conclusionSimilar oncological outcomes are observed after PTA and RPN for T1 RCC in elderly patients. CLINICAL RELEVANCE STATEMENT: Robot-assisted partial nephrectomy and percutaneous thermal ablation have similar oncological outcomes for T1a kidney cancer in patients over 75 years; however, operative time, decrease in renal function, and length of hospital stay were lower with ablation. KEY POINTS: • After adjusting model for age and ASA score, similar oncological outcomes are observed after percutaneous thermal ablation and robot-assisted partial nephrectomy for T1 renal cell cancer in elderly patients. • Operation time, length of hospital stay, and increase of creatinine serum level were higher in the robot-assisted partial nephrectomy group.

Indexed as

Carcinoma, Renal CellCatheter AblationKidney NeoplasmsRoboticsRobotic Surgical ProceduresAgedCreatinineHumansNephrectomyNephronsRetrospective StudiesTreatment OutcomeCreatinineAgedCarcinomaKidney neoplasmsNephrectomyThermal ablation

Identifiers

PMID37466710
OpenAlexW4384663058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.